ArticleMedicine2026
The role of long noncoding RNA myocardial infarction-associated transcript in hepatocellular carcinoma: Targeting miR-361-3p to regulate cell proliferation, invasion, and apoptosis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study aims to investigate the effects of long noncoding RNA myocardial infarction-associated transcript (lncRNA MIAT) targeting miR-361-3p on the proliferation, invasion, and apoptosis of hepatocellular carcinoma (HCC) cells. The expression levels of lncRNA MIAT and miR-361-3p were examined in both cancerous and adjacent non-tumorous tissues of HCC patients. Additionally, their expression was analyzed in THLE-2 and MHCC97L cells. MHCC97L cells were transfected to observe changes in relevant mRNA expression and alterations in cell proliferation, invasion, and apoptosis. Compared with adjacent non-tumorous tissues, cancerous tissues exhibited increased levels of lncRNA MIAT mRNA and decreased levels of miR-361-3p (P < .05). Elevated transcription levels of lncRNA MIAT were more prevalent in patients with lymph node metastasis and advanced TNM staging (P < .05). In MHCC97L cells, compared with THLE-2 cells, there was an increase in lncRNA MIAT mRNA and a decrease in miR-361-3p (P < .05). LncRNA MIAT and miR-361-3p were found to have potential binding sites and exhibit target regulation. Cells in the miR-NC group showed no significant changes in all indicators compared with the negative control group (P > .05). Conversely, cells with low expression of lncRNA MIAT and cyclin D1 mRNA and decreased cell proliferation and invasion numbers showed increased expression of miR-361-3p and phosphatase and tensin homolog mRNA and higher apoptosis rates (P < .05). The group with elevated expression levels demonstrated contrasting patterns (P < .05). LncRNA MIAT is upregulated in HCC tissues. Silencing lncRNA MIAT can elevate miR-361-3p levels, inhibiting the proliferation and invasion of MHCC97L cell structures and promoting apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.